Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Selinexor: Changing the paradigm in patients with TP53 wild-type endometrial cancer?

Mohamed A Gouda,Kyaw Z Thein

Med (New York, N.Y.)（2023）

Cited 0|Views10
No score
Abstract
Recurrent endometrial cancer (EC) remains a therapeutic challenge despite advancements in personalized medicine. SIENDO trial showed the potential clinical benefit of selinexor in patients with TP53 wild-type advanced/recurrent EC. The quest for novel therapeutic avenues and approaches continues as researchers seek a glimmer of hope in an area of uncertainty.
More
Translated text
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined